Market News

Patents in question invalidated based on obviousness.

The enlarged business will comprise 21 manufacturing centres and commercial operations across 60 countries.

Manufacturing projects in eco-friendly and biodegradable packaging, which is expected to surge in near future.

New perfeXion system, which generates around 100,000 data tags/min, makes an important contribution to quality assurance for downstream post-processing steps at the beginning of the value chain.

Developments in local manufacturing, regulatory strategies, market entry and harmonisation to be debated by MENA leaders and Government.

Effectively handles difficult-to-mix pharmaceutical ingredients.

First treatment approved in 5 years for adolescents aged 13-17 years with schizophrenia.

Actelion R&D unit to spin out into standalone company based and listed in Switzerland.

Issued claims are directed to a series of orally available small molecules and their use in treating epilepsy, neuropathic pain, and other neurological disorders.

New dosage strength expected to be available in first quarter of 2017.

Company expects to invest cost savings in its branded and generics business segments.

Clinical trial is the first of its kind to treat IBS symptoms by cannabinoid-containing chewing gum.

Disease prevalence can be monitored with a precision never before possible.

GenVec's AdenoVerse to be integrated into Intrexon's proprietary synthetic biology platform.

Investments include an LC-MS/MS, and GC-MS with head-space capability, for improved and rapid identification of trace unknown extractable compounds.

Site enlargement enables increased capacity for state-of-the-art quality control and storage.

Feasibility study to examine three different oral formulations engineered with Enteris’ Peptelligence platform.

Extends multi-year agreement in drug discovery with focus on cardiovascular and central nervous system disorders, immunology, infectious diseases and oncology.

The first chemically-defined, animal component-free, cell culture medium for T cells.

No admission of wrongdoing, No monetary payment by Endo.

Merck to pay BMS and Ono royalties on global sales of Keytruda through 2026, and lump-sum payment of $625 million.

Cold-EEZE will become Mylan's largest US OTC brand franchise.

Deal will enhance Lilly's existing pain management portfolio for migraine and adds potential near-term launch to its late-stage pipeline.

Company's subsidiary currently involved in patent litigation concerning this product.

Regulatory compliant, FDA-audited facility based in Mollet des Vallès, Spain.

The settlement and license agreement will strengthen Biogen's IP for leading oral therapy for multiple sclerosis.

Suliqua will be delivered in two pre-filled SoloSTAR pens, providing different dosing options that may help answer individual market and patient insulin needs.

leon nanodrugs' MJR technology offers reformulation options that address API solubility issues.

WHF therapy can be directly applied on a wound to stimulate the natural human wound healing process.

Transaction includes US commercialization rights for Onivyde for metastatic pancreatic cancer in adult patients.

No concerns raised by FDA related to the rolapitant IV efficacy or safety profile and additional clinical studies are not required.

Novo Nordisk to launch Fiasp in first half of 2017.

Product receives designations for both the BV treatment and prevention indications.

Comprehensive validation services for the Chinese market.

All programs (two promising clinical-stage programs targeting DNA damage and repair, and two novel pre-clinical programs) have first-in-class and best-in-class potential.

If the patent is ultimately upheld through all remaining challenges, Alimta would maintain US exclusivity until May 2022.

New study to evaluate combination of Lartruvo and Keytruda.

Company aims to increase production capacity to supply multiple commercial-scale therapeutic vaccines under development.

Collaboration will give Pierre Fabre the option to enter into exclusive negotiations to license global rights for the program in selected skin cancer conditions.

Expansionincludes the opening of two new process development centers in the US and China.

Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities.

Scientists can confirm, in one easy step, whether an antibody has been successfully conjugated.

Generis is the most sold pharmaceutical brand in Portugal, and is the #2 generic group in Portugal.

Deal expands Allergan's innovative GI [ipeline with ABI-M201 and ABI-M301, preclinical compounds targeting Uucerative colitis and Crohn's disease, as well as future compounds for irritable bowel syndrome.

KumaMax could provide hope celiac patients who try, but are unable to completely avoid gluten exposure in their diets,

JOTROL is being developed to remedy resveratrol’s poor bioavailability and dose limiting gastrointestinal side effects.

Company collaborating with all participants in the pharma supply chain to tackle to the epidemic of prescription drug abuse.

Ariad stockholders to receive $24.00 per share in cash.

A ready-to-use, stable and soluble, parenteral form of clopidogrel is feasible using the company's nanoemulsion platform technology.

Christi Shaw hired to lead Bio-Medicines; Conterno to assume additional geographic responsibilities, including Lilly USA leadership; Zulueta to lead International business.

Phase Ib/II studies to explore a novel immuno-oncology combination in hematological and solid tumours with high unmet medical need.

Noxxon continues transition to clinical oncology company.

PolyPeptide Laboratories' acquisition brings immediate access to additional large-scale capacity in synthesis, purification and isolation of peptides.

Concordia will continue to be responsible for the manufacturing and supply of Donnatal in all territories.

Appointment of Ian Clark as Non-Executive Director.

Website allows visitors to simply and quickly locate pertinent information.

Presentation provides new data regarding the mechanism of the ControLyo Technology.

Each company will separately pursue their own vaccine strategies in Europe.

Investigation reveals improper expense reimbursements.

Agreement includes the commercialization and development rights to the newly approved EU drug Zavicefta (ceftazidime-avibactam).

Computationally intelligent drug discovery platform receives two Fierce Innovation awards for Biotech Innovation and Best New Product.

Development and licence agreement is for pMDI inhaled triple therapy (VR2076) for asthma and COPD.

Oral Otezla receives positive NICE recommendation for adults with psoriatic arthritis.

Mr Wilkinson no longer President and CEO and a member of the Board.

Acquisition adds global portfolio of sterile injectables, robust pipeline, and manufacturing capabilities.

Novartis and Sunovion Pharmaceuticals strike agreement for three COPD treatments.

Caforio will succeed Lamberto Andreotti effective 2 May 2017.

Key products include Alloderm and Stratticem tissue matrices commonly used in breast reconstruction and abdominal wall surgeries.

The agreement also provides an option to have Lonza exclusively supply API for up to 20 years.

Acquisition of Encore Vision, to add first-in-class disease modifying topical treatment for presbyopia patients to the Novartis ophthalmology pipeline in an area of high unmet medical need and high prevalence

Agreement is the first step in TPI Enterprises’ plan to expand its presence in the UK market.

Labeling revisions also include updates to corresponding warning and addition of clinical data on superior efficacy of Chantix compared with bupropion or nicotine patch.

Pharmapack 2017: focus on tailor-made packaging. solutions

Guidelines include new recommendation to consider the use of Jardiance in people with type 2 diabetes and established cardiovascular disease to reduce the risk of cardiovascular death.

Authorized generic offered at more than 50% below wholesale acquisition cost of EpiPen auto-injector.

In its decision, the jury also concluded that Gilead “willfully” infringed upon the patent.

apceth Biopharma will perform clinical manufacturing, process validation activities and commercial manufacturing for LentiGlobin and Lenti-D drug product.

Acquisition will make Lonza a fully integrated solutions provider in oral delivery technologies and active ingredients to the consumer healthcare and nutrition markets.

Catalent Biologics will employ its proprietary GPEx cell line technology and ambr workstation to develop, optimize the process for expression, and manufacture antibodies for further investigation by MVI and its partners.

Laboratory and office facility to be constructed on the site by 2019.

Several late-stage pipeline drugs are expected to achieve blockbuster status by the end of 2022,

CDMO appoints Anders Högdin and Aaron Small to lead the growth of its pharmaceutical development services business in the US and Europe.

New shareholder, Axxamof Milan, Italy, will transfer certain therapeutic assets to the R&D programs of Acousia.

Additional storage expansion strengthens the facilities’ ability to meet increased customer demand in prefilled syringes.

Company will also close its Hopewell, New Jersey site and will not renew its lease at the Lake Union Steam Plant site in Seattle, Washington.

New once-a-day formulation indicated to improve blood sugar when used along with diet and exercise.

Actions will help to improve the company's financial profile.

Company expects the generic capsules will save up to $500 million during this upcoming season.

Users of LyoSpeed on Series 3 HT Evaporators report a greater percentage of samples yield dry powders than they have previously been able to achieve.

Acquisition would "fit perfectly with Lonza's Healthcare Continuum strategy".

Pharma manufacturers are feeling encouraged to explore new possibilities.

Lucentis the only treatment available for a wide range of CNV conditions.

"MEDI1814 has a unique mechanism among antibodies in clinical development and could provide a distinct approach to treating Alzheimer's disease."

New company will develop, to proof-of-concept, AP-101, a human monoclonal antibody targeting misfolded SOD1 for the treatment of amyotrophic lateral sclerosis.

Clinically proven and cost-effective solution for gastroesophageal reflux disease recently launched in China.

MJR technology offers reformulation options that can lead to a superior profile for an API.

Pharma giant says it complied with established competition law.

Helps shape better supply chain to pharmaceutical and healthcare Industries.

Move will allow the company to focus efforts and resources more fully on its core US Branded assets.

Investment enables the CDMO to provide a one-stop-shop service from lab-scale development to manufacturing of clinical batches and dossier compilation to specialised commercial manufacturing.

Combining nivolumab and ipilimumab could provide significant tumour reduction.

The deal allows Lonza to fully focus on developing its other technologies.

SP Scientific's whitepaper emphasis the importance of using external washers to remove particles from the outside of vials.

Brings specialist knowledge of modified release technologies, polymer engineering and science, solids, liquids, semi-solids, nasal delivery, and the switch from prescription to OTC medications

The CDMO’s initiatives include laboratory research for the preparation of APIs, with a particular focus on chiral molecules and emphasis on the principles of sustainable development and ‘green chemistry’.

UCL pioneers the engineering of novel nanoscale drug delivery vehicles, which can be tuned to release a range of cargos.

The new product, Laccure Pessary, will be manufactured, packaged and distributed globally from Recipharm’s facility in Karlskoga that specialises in the production of semi-solid products.

The Dolphin brand is currently the third largest on the Russian market for nasal rinsing.

As regulatory pressure increases companies are saving time and money with effective extractables and leachables programmes.

The added space will house state-of-the-art clean rooms and integrated best-in-class vision equipment.

T2DM therapies are capable of modifying the activity of insulin in the brain.

New entrants, as well as smaller companies, will expand the use of cell culture-based manufacturing methods to increase their presence.

Company to invest more than 100 million euro in dengue vaccine manufacturing plant in Germany

Partnership combines MolPort’s 6.3 Million HTS Compounds with StarDrop’s data analysis and compound design capabilities.

Enables detailed control in thawing of cell and gene therapies.

The silicone capmats reseal after each piercing and may be re-pierced many times without loss of function.

Mechanical thrombectomy is a more effective treatment than clot-busting drugs alone for acute stroke caused by blockage of a large blood vessel by a clot.

Company gains additional API capacity and major supply agreement with Roche

Company acquires two state-of-the-art facilities offering integrated softgel development, manufacturing and packaging.

Enables standardization and audit of remote freezing and thawing.